mTOR訊息傳遞路徑抑制劑於小細胞肺癌的抗癌效果之研究

Investigation the anti-cancer effects of mTOR signaling inhibitor in small cell lung cancer

李秀珠

每福敏(二甲雙胍) ； 小細胞肺癌 ； mTOR訊息傳遞路徑抑制劑 ； 聯合治療 ； metformin ； SCLC ； mTOR signaling inhibitor ； combination therapy

交通大學生物科技學系學位論文

2016年

碩士

梁美智

英文

肺癌位居於台灣十大癌症死因之首，其中小細胞肺癌(small cell lung cancer)占所有肺癌中比例約百分之十五，且與非小細胞肺癌相比具有高度侵襲性、迅速增長、早期傳播和抗藥性等特性。迄今為止，化學治療仍然是小細胞肺癌患者最主要的臨床治療方法。因此，在臨床上急需發展出嶄新的治療策略。在這項研究中，我們將研究mTOR訊息傳遞路徑抑制劑對於小細胞肺癌的抗癌效果，本研究選用二甲雙胍(Metformin, Met)作為mTOR訊息傳遞路徑抑制劑，Metformin是一種雙胍類藥物，為現在經過美國FDA核淮用於治療第二型糖尿病患者(T2D)的第一線用藥，其主要作用是透過抑制mTOR訊息傳遞路徑下游蛋白S6及4E-BP1和MAPK訊息傳遞路徑下游蛋白Erk 1/2的磷酸化。在實驗結果顯示，Metformin可以增強對小細胞肺癌的細胞毒殺性及促進癌細胞走向凋亡。然後，在研究中也發現Metformin與現階段臨床化療藥物配合使用後，能增強它們在小細胞肺癌的細胞毒性和誘導細胞凋亡的效果。總結以上之結果，本研究建議Metformin有潛力成為單獨或合併使用作為小細胞肺癌的標靶治療藥物。

The small cell lung cancer (SCLC) is a highly aggressive tumor with rapidly growth, early dissemination and development of drug resistance. To date, the chemotherapy remains the cornerstone of treatment in SCLC patients. In this study, we examined the anti-proliferative effects of metformin on SCLC. The metformin (Met) is a derivative of Biguanides and is now the most widely prescribed oral anti-diabetic agent worldwide, which mainly acts through inactivation of the mTOR pathway and suppression its downstream family proteins in many different types of cancers. Our results showed that the metformin enhanced cell toxicity with time- and concentration-dependent induced cell apoptosis in the H209 and H146 SCLC cell lines. Furthermore, the metformin inhibited cell proliferation through causing cell cycle arrested in G0/G1 and G2/M phase. AnnexinV/propidium iodide staining by flow cytometric exhibited nuclear feature of apoptosis with the increasing annexin V positive apoptotic cell proportion in a dose-dependent manner. In the analysis of the signaling transduction pathways, the mTOR and Erk 1/2 signaling proteins were affected by metformin treatments in SCLC cells. In addition, co-treatment with metformin does effectively enhance cisplatin, etoposide, topotecan or 5-fluorouracil mediated cell toxicity and can induce apoptosis. In summary, our results suggest that metformin may be a potential target therapeutic agent in the treatment of SCLC.

1. Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., and Kamarul, T. (2016). Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell death & disease 7, e2058.
   連結：
2. Ballou, L. M., and Lin, R. Z. (2008). Rapamycin and mTOR kinase inhibitors. Journal of chemical biology 1, 27-36.
   連結：
3. Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., and Thompson, C. B. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer research 67, 6745-6752.
   連結：
4. Byers, L. A., and Rudin, C. M. (2015). Small cell lung cancer: where do we go from here? Cancer 121, 664-672.
   連結：
5. Califano, R., Abidin, A. Z., Peck, R., Faivre-Finn, C., and Lorigan, P. (2012). Management of small cell lung cancer: recent developments for optimal care. Drugs 72, 471-490.
   連結：
6. Cantrell, L. A., Zhou, C., Mendivil, A., Malloy, K. M., Gehrig, P. A., and Bae-Jump, V. L. (2010). Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecologic oncology 116, 92-98.
   連結：
7. Chen, G., Xu, S., Renko, K., and Derwahl, M. (2012). Metformin Inhibits Growth of Thyroid Carcinoma Cells, Suppresses Self-Renewal of Derived Cancer Stem Cells, and Potentiates the Effect of Chemotherapeutic Agents. The Journal of Clinical Endocrinology & Metabolism 97, E510-E520.
   連結：
8. Cho, S. W., Yi, K. H., Han, S. K., Sun, H. J., Kim, Y. A., Oh, B. C., Park, Y. J., and Park do, J. (2014). Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. Molecular and cellular endocrinology 393, 24-29.
   連結：
9. Demedts, I. K., Vermaelen, K. Y., and van Meerbeeck, J. P. (2010). Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. The European respiratory journal 35, 202-215.
   連結：
10. Eisenberg-Lerner, A., Bialik, S., Simon, H. U., and Kimchi, A. (2009). Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell death and differentiation 16, 966-975.
    連結：
11. Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicologic pathology 35, 495-516.
    連結：
12. Gao, S., Jiang, J., Li, P., Song, H., Wang, W., Li, C., and Kong, D. (2015). Attenuating tumour angiogenesis: a preventive role of metformin against breast cancer. BioMed research international 2015, 592523.
    連結：
13. Ghobrial, I. M., Witzig, T. E., and Adjei, A. A. (2005). Targeting apoptosis pathways in cancer therapy. CA: a cancer journal for clinicians 55, 178-194.
    連結：
14. Glick, D., Barth, S., and Macleod, K. F. (2010). Autophagy: cellular and molecular mechanisms. The Journal of pathology 221, 3-12.
    連結：
15. Gouyer, V., Gazzeri, S., Bolon, I., Drevet, C., Brambilla, C., and Brambilla, E. (1998). Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 18, 188-196.
    連結：
16. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
    連結：
17. Hanna, R. K., Zhou, C., Malloy, K. M., Sun, L., Zhong, Y., Gehrig, P. A., and Bae-Jump, V. L. (2012). Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecologic oncology 125, 458-469.
    連結：
18. He, C., and Klionsky, D. J. (2009). Regulation mechanisms and signaling pathways of autophagy. Annual review of genetics 43, 67-93.
    連結：
19. Hirao, A., and Hoshii, T. (2013). Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia. Cancer science 104, 977-982.
    連結：
20. Huang, S., Bjornsti, M. A., and Houghton, P. J. (2003). Rapamycins: mechanism of action and cellular resistance. Cancer biology & therapy 2, 222-232.
    連結：
21. Iliopoulos, D., Hirsch, H. A., and Struhl, K. (2011). Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer research 71, 3196-3201.
    連結：
22. Inoki, K., Zhu, T., and Guan, K. L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590.
    連結：
23. Jokinen, E., and Koivunen, J. P. (2015). MEK and PI3K inhibition in solid tumors: rationale and evidence to date. Therapeutic advances in medical oncology 7, 170-180.
    連結：
24. Kitazono, S., Takiguchi, Y., Ashinuma, H., Saito-Kitazono, M., Kitamura, A., Chiba, T., Sakaida, E., Sekine, I., Tada, Y., Kurosu, K., et al. (2013). Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol 43, 1846-1854.
    連結：
25. Lai, S. W., Liao, K. F., Chen, P. C., Tsai, P. Y., Hsieh, D. P., and Chen, C. C. (2012). Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clinical lung cancer 13, 143-148.
    連結：
26. Lin, C.-C., Yeh, H.-H., Huang, W.-L., Yan, J.-J., Lai, W.-W., Su, W.-P., Chen, H. H. W., and Su, W.-C. (2013). Metformin Enhances Cisplatin Cytotoxicity by Suppressing Signal Transducer and Activator of Transcription–3 Activity Independently of the Liver Kinase B1–AMP-Activated Protein Kinase Pathway. American Journal of Respiratory Cell and Molecular Biology 49, 241-250.
    連結：
27. Ling, S., Tian, Y., Zhang, H., Jia, K., Feng, T., Sun, D., Gao, Z., Xu, F., Hou, Z., Li, Y., and Wang, L. (2014). Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel7402/5fluorouracil cells. Mol Med Rep 10, 2891-2897.
    連結：
28. Liu, B., Fan, Z., Edgerton, S. M., Deng, X. S., Alimova, I. N., Lind, S. E., and Thor, A. D. (2009). Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8, 2031-2040.
    連結：
29. Liu, J., Li, M., Song, B., Jia, C., Zhang, L., Bai, X., and Hu, W. (2013). Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urologic oncology 31, 264-270.
    連結：
30. Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., and Avruch, J. (2005). Rheb binds and regulates the mTOR kinase. Current biology : CB 15, 702-713.
    連結：
31. Lowe, S. W., and Lin, A. W. (2000). Apoptosis in cancer. Carcinogenesis 21, 485-495.
    連結：
32. Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., and Sonenberg, N. (2004). eIF4E--from translation to transformation. Oncogene 23, 3172-3179.
    連結：
33. Martelli, A. M., Evangelisti, C., Follo, M. Y., Ramazzotti, G., Fini, M., Giardino, R., Manzoli, L., McCubrey, J. A., and Cocco, L. (2011). Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Current medicinal chemistry 18, 2715-2726.
    連結：
34. Mendoza, M. C., Er, E. E., and Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in biochemical sciences 36, 320-328.
    連結：
35. Milella, M., Kornblau, S. M., Estrov, Z., Carter, B. Z., Lapillonne, H., Harris, D., Konopleva, M., Zhao, S., Estey, E., and Andreeff, M. (2001). Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. The Journal of clinical investigation 108, 851-859.
    連結：
36. Pietanza, M. C., and Rudin, C. M. (2012). Novel therapeutic approaches for small cell lung cancer: the future has arrived. Current problems in cancer 36, 156-173.
    連結：
37. Puglisi, M., Dolly, S., Faria, A., Myerson, J. S., Popat, S., and O'Brien, M. E. (2010). Treatment options for small cell lung cancer - do we have more choice? British journal of cancer 102, 629-638.
    連結：
38. Rodriguez-Lirio, A., Perez-Yarza, G., Fernandez-Suarez, M. R., Alonso-Tejerina, E., Boyano, M. D., and Asumendi, A. (2015). Metformin Induces Cell Cycle Arrest and Apoptosis in Drug-Resistant Leukemia Cells. Leukemia research and treatment 2015, 516460.
    連結：
39. Ruvinsky, I., Sharon, N., Lerer, T., Cohen, H., Stolovich-Rain, M., Nir, T., Dor, Y., Zisman, P., and Meyuhas, O. (2005). Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes & development 19, 2199-2211.
    連結：
40. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current biology : CB 14, 1296-1302.
    連結：
41. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M., and Cantley, L. C. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646.
    連結：
42. Shi, W. Y., Xiao, D., Wang, L., Dong, L. H., Yan, Z. X., Shen, Z. X., Chen, S. J., Chen, Y., and Zhao, W. L. (2012). Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell death & disease 3, e275.
    連結：
43. Siegel, R. L., Miller, K. D., and Jemal, A. (2016). Cancer statistics, 2016. CA: a cancer journal for clinicians 66, 7-30.
    連結：
44. Song, C. W., Lee, H., Dings, R. P., Williams, B., Powers, J., Santos, T. D., Choi, B. H., and Park, H. J. (2012). Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific reports 2, 362.
    連結：
45. Takahashi, A., Kimura, F., Yamanaka, A., Takebayashi, A., Kita, N., Takahashi, K., and Murakami, T. (2014). Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer cell international 14, 53.
    連結：
46. Tomic, T., Botton, T., Cerezo, M., Robert, G., Luciano, F., Puissant, A., Gounon, P., Allegra, M., Bertolotto, C., Bereder, J. M., et al. (2011). Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death and Disease 2, e199.
    連結：
47. Tsurutani, J., West, K. A., Sayyah, J., Gills, J. J., and Dennis, P. A. (2005). Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer research 65, 8423-8432.
    連結：
48. van Meerbeeck, J. P., Fennell, D. A., and De Ruysscher, D. K. M. (2011). Small-cell lung cancer. The Lancet 378, 1741-1755.
    連結：
49. Wang, L. W., Li, Z. S., Zou, D. W., Jin, Z. D., Gao, J., and Xu, G. M. (2008). Metformin induces apoptosis of pancreatic cancer cells. World journal of gastroenterology 14, 7192-7198.
    連結：
50. Wu, B., Li, S., Sheng, L., Zhu, J., Gu, L., Shen, H., La, D., Hambly, B. D., Bao, S., and Di, W. (2012). Metformin inhibits the development and metastasis of ovarian cancer. Oncol Rep 28, 903-908.
    連結：
51. Xie, Y., Peng, Z., Shi, M., Ji, M., Guo, H., and Shi, H. (2014). Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer. Molecular Medicine Reports.
    連結：
52. Yang, Z. J., Chee, C. E., Huang, S., and Sinicrope, F. A. (2011). The role of autophagy in cancer: therapeutic implications. Molecular cancer therapeutics 10, 1533-1541.
    連結：
53. Zakikhani, M., Blouin, M. J., Piura, E., and Pollak, M. N. (2010). Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast cancer research and treatment 123, 271-279.
    連結：
54. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., and Pollak, M. (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer research 66, 10269-10273.
    連結：
55. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation 108, 1167-1174.
    連結：
56. Zinn, R. L., Gardner, E. E., Marchionni, L., Murphy, S. C., Dobromilskaya, I., Hann, C. L., and Rudin, C. M. (2013). ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer Ther 12, 1131-1139.
    連結：
57. Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nature reviews Molecular cell biology 12, 21-35.
    連結：
58. Brodowska, K., Theodoropoulou, S., Meyer Zu Horste, M., Paschalis, E. I., Takeuchi, K., Scott, G., Ramsey, D. J., Kiernan, E., Hoang, M., Cichy, J., et al. (2014). Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol 45, 2311-2324.
59. Cooper, W. A., Lam, D. C., O'Toole, S. A., and Minna, J. D. (2013). Molecular biology of lung cancer. Journal of thoracic disease 5 Suppl 5, S479-490.
60. Eckardt, J. R., von Pawel, J., Pujol, J. L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Preston, A. J., Dane, G., and Ross, G. (2007). Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25, 2086-2092.
61. Janjetovic, K., Harhaji-Trajkovic, L., Misirkic-Marjanovic, M., Vucicevic, L., Stevanovic, D., Zogovic, N., Sumarac-Dumanovic, M., Micic, D., and Trajkovic, V. (2011). In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 668, 373-382.
62. Pópulo, H., Lopes, J. M., and Soares, P. (2012). The mTOR Signalling Pathway in Human Cancer. International Journal of Molecular Sciences 13, 1886-1918.
63. Park, K. S., Liang, M. C., Raiser, D. M., Zamponi, R., Roach, R. R., Curtis, S. J., Walton, Z., Schaffer, B. E., Roake, C. M., Zmoos, A. F., et al. (2011). Characterization of the cell of origin for small cell lung cancer. Cell Cycle 10, 2806-2815.
64. Sekido, Y., Fong, K. M., and Minna, J. D. (2003). Molecular genetics of lung cancer. Annual review of medicine 54, 73-87.
65. Xu, T., Liang, G., Yang, L., and Zhang, F. (2015). Prognosis of small cell lung cancer patients with diabetes treated with metformin. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 17, 819-824.